Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kiromic BioPharma stock | $2.15

Learn how to easily invest in Kiromic BioPharma stock.

Kiromic BioPharma Inc
+ $0.06 ( + 2.79%)

Kiromic BioPharma Inc is a biotechnology business based in the US. Kiromic BioPharma shares (KRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Kiromic BioPharma employs 19 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Kiromic BioPharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KRBP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kiromic BioPharma stock price (NASDAQ: KRBP)

Use our graph to track the performance of KRBP stocks over time.

Kiromic BioPharma shares at a glance

Information last updated 2021-10-17.
Latest market close$2.15
52-week range$1.81 - $12.11
50-day moving average $3.06
200-day moving average $5.63
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.24

Buy Kiromic BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kiromic BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiromic BioPharma price performance over time

Historical closes compared with the close of $2.15 from 2021-10-18

1 week (2021-10-12) 6.44%
1 month (2021-09-17) -37.86%
3 months (2021-07-19) -26.37%
6 months (2021-04-19) -75.57%
1 year (2020-10-19) -80.96%
2 years (2019-10-15) N/A
3 years (2018-10-15) N/A
5 years (2016-10-15) N/A

Kiromic BioPharma financials

Gross profit TTM $0
Return on assets TTM -180.54%
Return on equity TTM -425.08%
Profit margin 0%
Book value $0.66
Market capitalisation $30.4 million

TTM: trailing 12 months

Shorting Kiromic BioPharma shares

There are currently 38,678 Kiromic BioPharma shares held short by investors – that's known as Kiromic BioPharma's "short interest". This figure is 6.8% down from 41,499 last month.

There are a few different ways that this level of interest in shorting Kiromic BioPharma shares can be evaluated.

Kiromic BioPharma's "short interest ratio" (SIR)

Kiromic BioPharma's "short interest ratio" (SIR) is the quantity of Kiromic BioPharma shares currently shorted divided by the average quantity of Kiromic BioPharma shares traded daily (recently around 214877.77777778). Kiromic BioPharma's SIR currently stands at 0.18. In other words for every 100,000 Kiromic BioPharma shares traded daily on the market, roughly 180 shares are currently held short.

To gain some more context, you can compare Kiromic BioPharma's short interest ratio against those of similar companies.

However Kiromic BioPharma's short interest can also be evaluated against the total number of Kiromic BioPharma shares, or, against the total number of tradable Kiromic BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiromic BioPharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kiromic BioPharma shares in existence, roughly 0 shares are currently held short) or 0.0039% of the tradable shares (for every 100,000 tradable Kiromic BioPharma shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kiromic BioPharma.

Find out more about how you can short Kiromic BioPharma stock.

Kiromic BioPharma share dividends

We're not expecting Kiromic BioPharma to pay a dividend over the next 12 months.

You may also wish to consider:

Kiromic BioPharma overview

Kiromic BioPharma, Inc. , a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc. ; and Longwood University, as well as research and development collaboration agreements with Molipharma, S. R. L.

Frequently asked questions

What percentage of Kiromic BioPharma is owned by insiders or institutions?
Currently 32.322% of Kiromic BioPharma shares are held by insiders and 22.335% by institutions.
How many people work for Kiromic BioPharma?
Latest data suggests 19 work at Kiromic BioPharma.
When does the fiscal year end for Kiromic BioPharma?
Kiromic BioPharma's fiscal year ends in December.
Where is Kiromic BioPharma based?
Kiromic BioPharma's address is: 7707 Fannin, Houston, TX, United States, 77054
What is Kiromic BioPharma's ISIN number?
Kiromic BioPharma's international securities identification number is: US4976341051

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site